Leidos won a contract with a total value of $180 million to provide the Defense Health Agency with new virtual health capabilities for providers and patients.
The task order was awarded by DHA’s Program Executive Office Defense Healthcare Management Systems and has a 22-month period of performance if all options are exercised.
“Digital First addresses DHA’s goal of better outcomes, new processes, innovation and increased standardization based on evidence,” said Jason McCarthy, senior vice president of military and veterans health solutions at Leidos. “As part of our overall MHS GENESIS effort to enhance patient experience, we, along with Amwell, are looking forward to delivering this solution for DHA’s providers and patients.”
Under the contract, the Leidos Partnership for Defense Health will replace the Military Health System Video Connect solution with Amwell’s Converge platform. It will start at five initial sites followed by a phased enterprise roll-out. Digital First will bring new capabilities and enablement to MHS GENESIS, including digital technology.
“Through our world class platform Converge, Amwell is already enabling hybrid care across the commercial marketplace,” said Amwell Chairman and CEO Ido Schoenberg. “With this agreement, we are pleased to offer our unique capabilities and help improve access to quality care for MHS’ community of users,” Schoenberg said. “We are grateful for their service and honored to have been chosen to join Leidos in supporting the Department of Defense as it seeks to adopt and extend the benefits of hybrid care to the Military Health System.”
Using advanced, evidenced-based and commercially-available capabilities, LPDH is designed to quickly deliver an advanced digital health platform to meet patients where they are. The new platform includes self-guided wellness and behavioral health support.
Through integrated platform solutions, Leidos and Amwell will help reduce burdens on care teams, improve the mental health and wellness of beneficiaries, help reduce healthcare costs and optimize the effective use of DHA’s clinical resources across their global enterprise.